Ahmed and Raquel have a strong record in the industry. Thomas Turalski. Acerta Pharma works in close collaboration with research groups in Astra Zeneca, and takes an approach to discover, develop and deliver targeted novel 1 transformational medicines for patients suffering from hematological malignancies. Acerta’s lead drug, Calquence (acalabrutinib) was approved by the FDA under an accelerated approval … Founded in Netherlands in 2012 to develop treatments for cancers and autoimmune diseases, Acerta Pharma ran in stealth mode, driving investors and over 20 clinical trials for monotherapy and in combination with other targeted molecules. Acerta Pharma is a leader in the field of covalent binding technology and is applying this technology to create novel, highly selective therapies for cancer. Acerta Pharma B.v. (a Member Of The Astrazeneca Group) - email id & phone of 2 top management contacts like Founder, CEO, CFO, CMO, CTO, Marketing or HR or Finance head & all company details. He led the licensing negotiations with MSD and provided the seed capital. Acerta Pharma was founded in 2013 and is based in San Carlos, California. Our multiparametric phospho-proteomic platform enables the characterization of activated signaling networks within complex tissues and in discrete cell subsets. 3.5. Acerta-pharma uses 4 email formats, with first_initial '.' Before that, Dr Hamdy co-founded Acerta Pharma, a pharmaceutical development company and member of the AstraZeneca plc, and served as its head of early clinical development from January 2015 to June 2019, as chief executive officer from February 2013 to January 2015, as chief medical officer from February 2013 to January 2015 and as a member of the board from … At our recently expanded site at Oss in the Netherlands, we have core capabilities in target identification, target validation, lead generation and compound optimization. Now Acerta Pharma is worth $7 billion. In February 2016, AstraZeneca acquired a majority share of Acerta Pharma via a USD $4 billion investment and is a committed partner to the development of these innovative drugs. +1 908-********. SECTOR In February 2016, AstraZeneca acquired a majority share of Acerta Pharma via a USD $4 billion investment and is a committed partner to the development of these innovative drugs. Redx Pharma is a UK-based company developing new drug candidates using the broad-based potential of its innovative Redox Switch™ platform. t*****@percept***. Basilea was founded in 2000 as a spin-out from Roche and is headquartered in the heart of the life sciences hub of Basel. Acerta Pharma was sold to Astra Zeneca in February 2016. AstraZeneca is not responsible for the privacy policy of any third-party websites. Vincera’s chief executive is Ahmed Hamdy – a founder of Acerta Pharma that was acquired by AstraZeneca in 2016 in a $7 billion deal focused on cancer drug Calquence (acalabrutinib). Management Team’s Contribution. Our Translational Medicine (TM) team are actively implementing MRD endpoints in our clinical trials to understand what treatments can drive to MRD undetectable levels. Snapshot. Most recently, Mr. Salva served as a Founder and Vice President of Operations for Acerta Pharma B.V., where he focused on key growth … SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Designation based on positive results from two Phase III trials. Our novel, validated approach allows Redx Pharma to progress new drug development programs with lower risk and greater speed to clinical trials. Founded 2010. Email formats. Acerta Pharma is a leader in the field of covalent binding technology and is applying this technology to create a range of highly selective therapies for cancer. See Wayne P Rothbaum's compensation, career history, education, & memberships. last (ex. Wayne P Rothbaum is President/Managing Director/Founder at Quogue Capital LLC. 3.5 out of 5 stars. Co-Founder / Head of Biology Covalution Pharma BV jul. Dr. Ahmed Hamdy is an independent Board Director and Clinical Advisor of Andes Biotechnologies. Working together Acerta and AstraZeneca are focused on Innovative Clinical Strategies to enable us to combine our extensive oncology portfolio of cancer therapies. Acerta Pharma is a leader in the field of covalent binding technology and is applying this technology to create novel, highly selective therapies for cancer. In her past career she was Associate Director-Project & Portfolio Management at Gilead Sciences, Inc., Chief Operating Officer of Acerta Pharma BV and Chief Oncology Operations & Alliances at Pharmacyclics LLC. 2013 • Developed ibrutinib from preclinical through Phase 2 in < 3 years • All three Phase 2 studies garnered Break-Through Designation and Accelerated Approvals. 2019 6 jaar 5 maanden. Acerta Pharma provides drug discovery and development services for oncology and autoimmune diseases. Show profile. Mr. Francisco Salva has over 20 years of experience in biotechnology finance, venture capital and operating roles. Acerta Pharma B.V. operates a biotechnology company. Edward is Founder and Managing Partner at BioGeneration Ventures (BGV) and combines over 20 years of experience in venture capital, pharma licensing, drug development and translational research. Acerta Pharma B.V. (A member of the AstraZeneca Group) | 6,052 followers on LinkedIn. Private San Francisco Companies (Top 10K), United States Biotechnology Companies (Top 10K), Private San Francisco Bay Area Companies (Top 10K). Yomara Gomez. He is a Founder of Acerta Pharma BV and served as its Vice President of Operations, until the sale of 55% control to AstraZeneca for $4 billion. Get weekly updates, new jobs, and reviews. Merck 9 jaar Research Fellow Merck jan. 2009 - jun. WhatsApp acquired by Facebook). Acerta Pharma. Prior to that he was co-founder of Acerta Pharma, spinning out the covalent BTK inhibitor series from MSD into Acerta Pharma, that in 2017 received accelerated approval for mantle cell lymphoma from the FDA. He also brought a very experienced team into the company from the outset, which led to leading US-based venture capital groups to invest into the company. The Company focuses on the discovery and development of drugs for treating oncology and autoimmune diseases. Jean-Christophe’s extensive work history includes writing software for safety-critical systems for leaders in the transportation industry, including QNX and Bombardier. Edward co-founded Acerta Pharma and served on its board until its trade-sale to AstraZeneca. This is the Acerta Pharma company profile. Co-founder Acerta Pharma B.V. (A member of the AstraZeneca Group) feb. 2013 - jun. BioGeneration Ventures co-founded Acerta Pharma in 2013 with a team of seasoned drug development professionals and other investors. 6. Founded Date 2013; Founders Ahmed Hamdy, Tjeerd Barf; Operating Status Active; Last Funding Type Series A; Legal Name AstraZeneca UK Limited; Company Type For Profit; Contact Email info@acerta-pharma.com; Phone Number 650-591-2800 Founder of Calistoga Pharmaceuticals, board member and former Chief Scientific Officer of Acerta Pharma to help guide future of company focused on ground-breaking therapy for CNS-related edema And that’s not just on paper. He is also on the Board of Directors for Remedy Pharmaceuticals, is a Senior Advisor to Frazier Healthcare Partners, and serves as a scientific advisor to several small pharma companies. The company has utilized its proprietary discovery platform to successfully develop a portfolio of competitively differentiated clinical … Acerta Pharma was acquired by AstraZeneca in February 2016. Three years after inception, Acerta Pharma was brought under the control of AstraZeneca after a majority equity investment in Q1 of 2016. This link will take you to a site maintained by a third party who is solely responsible for its content. Listed Company. Developing novel targeted therapeutics for the treatment of cancer. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. Acerta founded. He is a founder of Acerta Pharma, a member of the AstraZeneca Group, and has previously served as the Chief Executive and Medical Officer. Picture credits: Elastic Elastic. Acerta Pharma is focused on the development of covalent binding technology solutions to create therapies for cancer. Our vision is to develop innovative hematology medicines that improve outcomes and enhance the lives of patients. j.smith@acerta-pharma.com) being used 73% of the time. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization, Auto-generated name of transaction (e.g. +1 646-********. 6 reviews. Shanghai-based Alebund Pharmaceuticals announced Monday that they raised a $60 million Series B led by Quan Capital, the VC firm from Zai Lab co-founder and CEO Samantha Du. Why Join Us. Co-Founder & Clinical Operations Executive: Allard Kaptein Ph.D: Co-Founder & Executive, Discovery: Ahmed Hamdy MD: Co-Founder & Medical Executive All content is posted anonymously by employees working at Acerta Pharma. Dr. Ahmed Hamdy is a founder of Acerta Pharma and its former Chief Executive and Medical Officer. Beginning in 2012, Mr. Rothbaum served as the co-founder and largest investor of Acerta Pharma, B.V., a Dutch biotech focused on developing selective, covalent small molecules to treat cancer and inflammation. ... Acerta Pharma … Show profile. Acerta Pharma BV develops drugs for oncology and autoimmune diseases. United Kingdom. Glassdoor gives you an inside look at what it's like to work at Acerta Pharma, including salaries, reviews, office photos, and more. | Acerta Pharma has the responsibility of developing both internally discovered compounds as well as AstraZeneca sourced compounds for hematological malignancies. Presently, Maria Fardis occupies the position of President, Chief Executive Officer & Director at Iovance Biotherapeutics, Inc. Founders: Shay Banon, Simon Willnauer, Steven Schuurman, Uri Boness Dr. Hamdy has 20 years of clinical research experience in pharmaceutical drug development, seven of which were in academic medical research. We encourage you to read the privacy policy of every website you visit. Jean-Christophe Petkovich has over 10 years of experience in data analysis, pattern recognition, statistical modelling, and machine learning. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. US-44652 Last Updated 11/20. Redx Pharma. Active, Closed, Last funding round type (e.g. The Oss research centre is based in the heart of the Pivot Park Biotechnology Campus and has established relationships with both academic and commercial partners in Europe. Acerta Pharma Careers and Employment | Indeed.com. In 2012, Mr. Rothbaum co-founded, and was the Executive Chairman of Acerta Pharma, a private life sciences company, he later sold to AstraZeneca. 2011 - jan. 2013 1 jaar 7 maanden. They co-founded Acerta Pharma in 2013 and developed BTK inhibitor, acalabrutinib (now Calquence, $511 M annual US revenue, 2020 1). Name of the organization that made the acquisition, Total amount raised across all funding rounds, Total number of employee profiles an organization has on Crunchbase, Total number of investment firms and individual investors, Descriptive keyword for an Organization (e.g. AstraZeneca provides this link as a service to website visitors. All rights reserved. Plexxikon USA Acquired Plexxikon® is a leader in the discovery and development of novel, small molecule pharmaceuticals. Richard Lin is the founder of Acuta Capital Partners Prior to founding Acuta Capital, Rich was a partner at Three Arch Partners, LP, a healthcare focused venture capital firm.